Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study

C. J. Punt; Y. L. Kamm; D. J. Wagener

doi:https://doi.org/10.1097/00001813-199706000-00006

Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study

C. J. Punt, Y. L. Kamm, D. J. Wagener

Other Departments

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally. Two daily peak delivery periods (PDP), during which 65% of the daily dose was administered, were investigated: from 18.00 to 0.30 h and from 0.00 to 06.30 h. The maximal tolerated dose of 5-FU was 2800 mg/m2/48 h, with a PDP from 18.00 to 0.30 h

Original language	English
Pages (from-to)	454-458
Journal	Anti-Cancer Drugs
Volume	8
Issue number	5
DOIs	https://doi.org/10.1097/00001813-199706000-00006
Publication status	Published - 1997

Access to Document

https://doi.org/10.1097/00001813-199706000-00006

Cite this

@article{81900089412a49e980a07db0c2b0953e,

title = "Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study",

abstract = "In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally. Two daily peak delivery periods (PDP), during which 65% of the daily dose was administered, were investigated: from 18.00 to 0.30 h and from 0.00 to 06.30 h. The maximal tolerated dose of 5-FU was 2800 mg/m2/48 h, with a PDP from 18.00 to 0.30 h",

author = "Punt, {C. J.} and Kamm, {Y. L.} and Wagener, {D. J.}",

year = "1997",

doi = "https://doi.org/10.1097/00001813-199706000-00006",

language = "English",

volume = "8",

pages = "454--458",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study

AU - Punt, C. J.

AU - Kamm, Y. L.

AU - Wagener, D. J.

PY - 1997

Y1 - 1997

N2 - In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally. Two daily peak delivery periods (PDP), during which 65% of the daily dose was administered, were investigated: from 18.00 to 0.30 h and from 0.00 to 06.30 h. The maximal tolerated dose of 5-FU was 2800 mg/m2/48 h, with a PDP from 18.00 to 0.30 h

AB - In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally. Two daily peak delivery periods (PDP), during which 65% of the daily dose was administered, were investigated: from 18.00 to 0.30 h and from 0.00 to 06.30 h. The maximal tolerated dose of 5-FU was 2800 mg/m2/48 h, with a PDP from 18.00 to 0.30 h

U2 - https://doi.org/10.1097/00001813-199706000-00006

DO - https://doi.org/10.1097/00001813-199706000-00006

M3 - Article

C2 - 9215607

SN - 0959-4973

VL - 8

SP - 454

EP - 458

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 5

ER -